Literature DB >> 8896045

Pharmacokinetic changes of methotrexate after intravenous administration to streptozotocin-induced diabetes mellitus rats.

J M Park1, C H Moon, M G Lee.   

Abstract

The pharmacokinetic changes of methotrexate (MTX) were investigated after 1-min intravenous (iv) administration of MTX, 8 mg/kg, to the control and the streptozotocin-induced diabetes mellitus (SIDM) rats. After 1-min iv infusion of MTX, plasma concentrations of MTX declined polyexponentially for both groups of rats. In the SIDM rats, the plasma concentrations of MTX were significantly lower up to 5 min, however, significantly higher from 60 min than those in the control rats. In the SIDM rats, the volume of distribution at steady state was significantly higher (1010 versus 265 ml/kg) than that in the control rats, and this was due to the significantly increased unbound fraction of MTX (73.0 versus 58.1%) in serum of SIDM rats. This resulted in a significantly increased mean residence time (53.2 versus 13.8 min) in the SIDM rats. All 12 control rats survived until sacrificed (24 hr), however, 6 out of 15 SIDM rats died within 6 h after iv administration of MTX, suggesting that the iv doses of MTX in diabetes mellitus patients may need to be modified if the present rat data could be extrapolated to human beings.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8896045

Source DB:  PubMed          Journal:  Res Commun Mol Pathol Pharmacol        ISSN: 1078-0297


  10 in total

Review 1.  Drug disposition in pathophysiological conditions.

Authors:  Adarsh Gandhi; Bhagavatula Moorthy; Romi Ghose
Journal:  Curr Drug Metab       Date:  2012-11       Impact factor: 3.731

2.  Effect of CYP3A1(23) induction on clarithromycin pharmacokinetics in rats with diabetes mellitus.

Authors:  Yu C Kim; Joo H Lee; So H Kim; Myung G Lee
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

3.  Telithromycin pharmacokinetics in rat model of diabetes mellitus induced by alloxan or streptozotocin.

Authors:  Joo H Lee; Myung G Lee
Journal:  Pharm Res       Date:  2008-05-14       Impact factor: 4.200

4.  Constitutive androstane receptor mediates the induction of drug metabolism in mouse models of type 1 diabetes.

Authors:  Bingning Dong; Mohammed Qatanani; David D Moore
Journal:  Hepatology       Date:  2009-08       Impact factor: 17.425

Review 5.  Strategies for preclinical pharmacokinetic investigation in streptozotocin-induced diabetes mellitus (DMIS) and alloxan-induced diabetes mellitus (DMIA) rat models: case studies and perspectives.

Authors:  Nuggehally R Srinivas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-03-06       Impact factor: 2.441

Review 6.  Immunosuppression for in vivo research: state-of-the-art protocols and experimental approaches.

Authors:  Rita Diehl; Fabienne Ferrara; Claudia Müller; Antje Y Dreyer; Damian D McLeod; Stephan Fricke; Johannes Boltze
Journal:  Cell Mol Immunol       Date:  2016-10-10       Impact factor: 11.530

7.  Study of the pharmacokinetic changes of Tramadol in diabetic rats.

Authors:  Hoda Lavasani; Behjat Sheikholeslami; Yalda H Ardakani; Mohammad Abdollahi; Lida Hakemi; Mohammad-Reza Rouini
Journal:  Daru       Date:  2013-03-07       Impact factor: 3.117

8.  Commentary on: "study of the pharmacokinetic changes of tramadol in diabetic rats" is the handicapped renal pathway in DMIS contributing for the increased bioavailability of tramadol?

Authors:  Nuggehally R Srinivas
Journal:  Daru       Date:  2013-03-15       Impact factor: 3.117

9.  Effects of Diabetes Mellitus on the Disposition of Tofacitinib, a Janus Kinase Inhibitor, in Rats.

Authors:  Eun Hye Gwak; Hee Young Yoo; So Hee Kim
Journal:  Biomol Ther (Seoul)       Date:  2020-07-01       Impact factor: 4.634

Review 10.  Imbalance of Drug Transporter-CYP450s Interplay by Diabetes and Its Clinical Significance.

Authors:  Yiting Yang; Xiaodong Liu
Journal:  Pharmaceutics       Date:  2020-04-11       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.